Acadian Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-753,140
| Closed | -$4.4M | – | 2054 |
|
|
2022
Q4 | $4.4M | Buy |
753,140
+123,841
| +20% | +$651K | 0.02% | 480 |
|
|
2022
Q3 | $4.21M | Sell |
629,299
-214,026
| -25% | -$1.3M | 0.02% | 446 |
|
|
2022
Q2 | $3.55M | Buy |
843,325
+49,219
| +6% | +$195K | 0.02% | 493 |
|
|
2022
Q1 | $2.67M | Buy |
794,106
+11,293
| +1% | +$35.8K | 0.01% | 605 |
|
|
2021
Q4 | $2.46M | Buy |
782,813
+82,473
| +12% | +$274K | 0.01% | 607 |
|
|
2021
Q3 | $2.29M | Buy |
700,340
+87,629
| +14% | +$307K | 0.01% | 646 |
|
|
2021
Q2 | $2.59M | Buy |
612,711
+79,138
| +15% | +$335K | 0.01% | 638 |
|
|
2021
Q1 | $2.66M | Buy |
533,573
+430,297
| +417% | +$3.48M | 0.01% | 654 |
|
|
2020
Q4 | $1.3M | Sell |
103,276
-8,909
| -8% | -$102K | 0.01% | 901 |
|
|
2020
Q3 | $1.1M | Sell |
112,185
-47,143
| -30% | -$465K | ﹤0.01% | 871 |
|
|
2020
Q2 | $1.58M | Sell |
159,328
-25,732
| -14% | -$247K | 0.01% | 805 |
|
|
2020
Q1 | $1.64M | Sell |
185,060
-46,108
| -20% | -$455K | 0.01% | 658 |
|
|
2019
Q4 | $2.13M | Sell |
231,168
-34,701
| -13% | -$246K | 0.01% | 668 |
|
|
2019
Q3 | $1.56M | Sell |
265,869
-74,833
| -22% | -$794K | 0.01% | 756 |
|
|
2019
Q2 | $4.09M | Sell |
340,702
-194,471
| -36% | -$2.09M | 0.02% | 440 |
|
|
2019
Q1 | $6.46M | Sell |
535,173
-121,331
| -18% | -$1.79M | 0.03% | 386 |
|
|
2018
Q4 | $8.24M | Sell |
656,504
-273,268
| -29% | -$3.77M | 0.04% | 300 |
|
|
2018
Q3 | $13.8M | Sell |
929,772
-11,510
| -1% | -$181K | 0.06% | 250 |
|
|
2018
Q2 | $15.8M | Buy |
941,282
+95,863
| +11% | +$1.86M | 0.07% | 242 |
|
|
2018
Q1 | $19.4M | Buy |
845,419
+547,383
| +184% | +$12.2M | 0.08% | 198 |
|
|
2017
Q4 | $7.71M | Buy |
+298,036
| New | +$6M | 0.03% | 309 |
|
|
2016
Q4 | – | Sell |
-65,484
| Closed | -$661K | – | 1807 |
|
|
2016
Q3 | $661K | Sell |
65,484
-209,654
| -76% | -$2.29M | ﹤0.01% | 761 |
|
|
2016
Q2 | $3.09M | Buy |
275,138
+172,735
| +169% | +$2.2M | 0.02% | 454 |
|
|
2016
Q1 | $1.4M | Buy |
102,403
+59,296
| +138% | +$853K | 0.01% | 593 |
|
|
2015
Q4 | $818K | Buy |
43,107
+28,185
| +189% | +$613K | ﹤0.01% | 722 |
|
|
2015
Q3 | $279K | Buy |
+14,922
| New | +$254K | ﹤0.01% | 853 |
|
Acadian Asset Management's CNCE Position: Q1 2023 in Review
Acadian Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 753,140 shares — an estimated $4.4M sold.
Acadian Asset Management first reported a position in CNCE in Q3 2015 and held it in 26 quarters. The position peaked at $19.4M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Acadian Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Acadian Asset Management sold 753,140 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.4M.
- Acadian Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 26 quarters.
- Acadian Asset Management's Concert Pharmaceuticals, Inc. position peaked at $19.4M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.